All Stories

  1. Cell-autonomous cytotoxicity of type I interferon responseviainduction of endoplasmic reticulum stress
  2. Modeling estrogen receptor-positive breast cancers in mice: is it the best we can do?: Table 1
  3. Peromyscus as a model of human disease
  4. Regulation of p21 during diabetes-associated stress of the endoplasmic reticulum
  5. Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress
  6. Polycystin-1 and polycystin-2 are involved in the acquisition of aggressive phenotypes in colorectal cancer
  7. A crosstalk between p21 and UPR-induced transcription factor C/EBP homologous protein (CHOP) linked to type 2 diabetes
  8. Advanced glycation end-products induce endoplasmic reticulum stress in human aortic endothelial cells
  9. Allelic Frequency in Human SNPs Predicts the Rate of Non-Synonymous Nucleotide Substitutions between Human and Chimpanzee Genes
  10. Notch3 marks clonogenic mammary luminal progenitor cells in vivo
  11. MicroRNAs in the tumour microenvironment: big role for small players
  12. p53 antagonizes the unfolded protein response and inhibits ground glass hepatocyte development during endoplasmic reticulum stress
  13. Selection of p53-Deficient Stromal Cells in the Tumor Microenvironment
  14. Growth Hormone-Releasing Hormone Receptor Splice Variant 1 is Frequently Expressed in Oral Squamous Cell Carcinomas
  15. Tackling transcription factors: challenges in antitumor therapy
  16. Growth hormone-releasing hormone: not only a neurohormone
  17. ERp29 regulates response to doxorubicin by a PERK-mediated mechanism
  18. p21/waf1 and smooth-muscle actin α expression in stromal fibroblasts of oral cancers
  19. Immunohistochemical Expression of Notch Signaling in the Lining Epithelium of Periapical Cysts
  20. GHRH and wound healing
  21. Essential role for p53/p21-mediated signaling in the regulation of stromal fibroblast/cancer cell interaction and therapeutic efficacy
  22. Acceleration of wound healing by growth hormone-releasing hormone and its agonists
  23. Atypical induction of the unfolded protein response by mifepristone
  24. Evaluation of Re and 99m Tc Complexes of 2-(4′-Aminophenyl)benzothiazole as Potential Breast Cancer Radiopharmaceuticals
  25. Editorial
  26. CHOP-dependent Regulation of p21/waf1 During ER Stress
  27. p21/waf1 and Smooth-Muscle Actin α Expression in Stromal Fibroblasts of Oral Cancers
  28. Regulation of Tumor-Stromal Fibroblast Interactions: Implications in Anticancer Therapy
  29. ERp29, an endoplasmic reticulum secretion factor is involved in the growth of breast tumor xenografts
  30. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132
  31. Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors
  32. Fibroblast independency in tumors: implications in cancer therapy
  33. P53 mutations in stromal fibroblasts sensitize tumors against chemotherapy
  34. Expression of growth hormone–releasing hormone receptor splice variant 1 in primary human melanomas
  35. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor
  36. Expression of ERp29, an Endoplasmic Reticulum Secretion Factor in Basal-Cell Carcinoma
  37. Expression of growth hormone-releasing hormone (GHRH) and splice variant of GHRH receptors in normal mouse tissues
  38. Anatomically independent tumors revisited
  39. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice
  40. Editorial [Hot Topic: GHRH Analogs and Cancer (Guest Editor: Hippokratis Kiaris )]
  41. Meet The Guest Editor
  42. Estrogen receptor alpha gene polymorphism and systemic lupus erythematosus: a possible risk?
  43. Evidence for Nonautonomous Effect of p53 Tumor Suppressor in Carcinogenesis
  44. Extrapituitary Effects of the Growth Hormone-Releasing Hormone
  45. Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers
  46. Modulation of Notch Signaling Elicits Signature Tumors and Inhibits Hras1-Induced Oncogenesis in the Mouse Mammary Epithelium
  47. Tumour–stroma interactions in carcinogenesis: Basic aspects and perspectives
  48. Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists
  49. Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor
  50. Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists
  51. Expression of growth hormone-releasing hormone in human primary endometrial carcinomas
  52. Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs
  53. A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice
  54. Direct action of growth hormone-releasing hormone agonist JI-38 on normal human fibroblasts: Evidence from studies on cell proliferation and c-myc proto-oncogene expression
  55. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses
  56. Suppression of tumor growth by growth hormone-releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin-like growth factor II in H-69 small cell lung carcinoma
  57. Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of U-87MG Human Glioblastoma in Nude Mice
  58. Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma
  59. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide
  60. Apoptosis Versus Necrosis: Which Should Be the Aim of Cancer Therapy?
  61. Apoptosis Versus Necrosis: Which Should Be the Aim of Cancer Therapy?
  62. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro
  63. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone
  64. Genetic Instability in Renal Cell Carcinoma
  65. Microsatellite instability and loss of heterozygosity in human pterygia
  66. Microsatellite Instability and Loss of Heterozygosity in Primary Breast Tumours
  67. Mutations and Expression of therasFamily Genes in Leukemias
  68. TGF-beta 1 overexpression in breast cancer
  69. Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors
  70. Instability at the H-ras minisatellite in human atherosclerotic plaques
  71. Loss of Heterozygosity and Microsatellite Instability in Human Atherosclerotic Plaques
  72. Quantitation of the allelic imbalance provides evidence on tumour heterogeneity: a hypothesis
  73. Microsatellite instability in patients with chronic obstructive pulmonary disease
  74. Detection of herpesvirus-like DNA sequences in Mediterranean Kaposi's sarcoma
  75. Microsatellite Instability in Human Atherosclerotic Plaques
  76. Loss of heterozygosity at 9p and 17q in human laryngeal tumours
  77. MUTATIONS OF RAS GENES IN HUMAN TUMORS (REVIEW)
  78. DETECTION OF K-RAS MUTATIONS IN NONSMALL CELL LUNG-CARCINOMA
  79. DETECTION OF ACTIVATING MUTATIONS IN THE RAS FAMILY GENES IN CYTOLOGICAL SPECIMENS FROM LUNG-TUMORS
  80. INSTABILITY AT MICROSATELLITE SEQUENCES IN SPONTANEOUSLY ABORTED HUMAN EMBRYOS PROVIDES EVIDENCE FOR A NOVEL MECHANISM FOR RECURRENT MISCARRIAGES
  81. Instability at the H-ras Minisatellite Is Associated with the Spontaneous Abortion of the Embryo
  82. ANALYSIS OF H-RAS, K-RAS AND N-RAS GENES FOR EXPRESSION, MUTATION AND AMPLIFICATION IN LARYNGEAL TUMORS
  83. ACTIVATING MUTATIONS OF RAS FAMILY GENES IN PROSTATIC-CANCER
  84. LOSS OF HETEROZYGOSITY ON CHROMOSOME-8 IN SQUAMOUS-CELL CARCINOMAS OF THE HEAD AND NECK
  85. A METHOD TO DETECT AND QUANTITATE THE EXPRESSION OF NORMAL VERSUS MUTANT H-RAS TRANSCRIPTS AT CODON-12
  86. LOSS OF HETEROZYGOSITY AND MICROSATELLITE INSTABILITY OF THE H-RAS GENE IN CANCER OF THE HEAD AND NECK
  87. ACTIVATING MUTATIONS IN THE K-RAS GENE IN ULCERATIVE-COLITIS AND CROHNS-DISEASE
  88. RAS GENE-MUTATIONS ARE A RARE EVENT IN HUMAN UVEAL AND CUTANEOUS MELANOMAS